Related Experiment Videos
Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study
1Department of Psychological Medicine, St Bartholomew's Hospital, London, United Kingdom.
Acta Psychiatrica Scandinavica
|October 1, 1993
Summary
Lithium augmentation therapy effectively treated major depression resistant to sertraline (antidepressant medication). Many patients responded quickly to lithium carbonate, even at low serum levels, with no significant side effects observed.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Major depression is a common psychiatric disorder.
- Treatment resistance is a significant challenge in managing major depression.
- Sertraline is a commonly prescribed selective serotonin reuptake inhibitor (SSRI) for depression.
Purpose of the Study:
- To investigate the efficacy of lithium augmentation therapy in patients with major depression resistant to sertraline treatment.
- To determine if serum lithium levels correlate with treatment response.
Main Methods:
- Eleven patients diagnosed with DSM-III-R major depression and resistant to sertraline were enrolled.
- Patients received adjunctive lithium carbonate at doses of 400 mg or 800 mg nightly, alongside their existing sertraline regimen.
- Treatment response and serum lithium levels were monitored.
Main Results:
- Seven out of eleven patients (64%) showed a positive response to lithium augmentation within one week.
- Treatment response was not correlated with serum lithium levels.
- Effective responses were observed even with low serum lithium levels (as low as 0.3 mEq/l).
- No significant adverse side effects were reported during the study.
Conclusions:
- Lithium augmentation is a potentially effective strategy for sertraline-resistant major depression.
- Low serum lithium levels may be sufficient for achieving therapeutic effects.
- This augmentation approach appears well-tolerated in the studied patient population.